泰格医药 (300347.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

59.9x

EV/EBITDA

36.4x

Market Cap

CNY 42.33B

MomentumView details →

1D Return

−9.58%

YTD Return

−11.82%

RSI (14)

46.9

ValuationView details →

P/E (Fwd)

59.9x

EV/EBITDA

36.4x

Market Cap

CNY 42.33B

RSI (14)

46.9

MomentumView details →

1D Return

−9.58%

YTD Return

−11.82%

ProfitabilityView details →

Gross Margin

26.64%

Net Margin

10.91%

EBITDA Margin

17.88%

ROE (TTM)

3.69%

ROA (TTM)

2.68%

Asset Turnover

0.25x

GrowthView details →

Revenue YoY

+8.65%

EPS YoY

+134.70%

FCF YoY

+19.07%

Revenue CAGR 3Y

−1.20%

EPS CAGR 3Y

−23.47%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−CNY 0.53

EPS Surprise

−477.79%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.33

Avg Surprise (4Q)

−477.79%

Rev Surprise

−0.23%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

2.30x

Quick Ratio

2.28x

Div Yield

0.25%

Div Rate

CNY 0.13

Div Growth 1Y

−58.00%

Financials snapshotView financials →

Revenue (TTM)

7.07B

Net Income (TTM)

771.46M

Op. CF (TTM)

1.24B

Next earningsOct 22, 2026 →

Latest newsMore news →

Tigermed reported a net loss of 413 million yuan attributable to shareholders for the first half of 2026, swinging from a profit of 383 million yuan a year earlier, while revenue grew 14.06% year-on-year to 3.708 billion yuan.8d ago

Similar companies

华测检测300012.SZ 富乐德301297.SZ 康龙化成300759.SZ 南网能源003035.SZ 华大基因300676.SZ 百普赛斯301080.SZ Find similar companies →

Latest newsMore news →

Tigermed reported a net loss of 413 million yuan attributable to shareholders for the first half of 2026, swinging from a profit of 383 million yuan a year earlier, while revenue grew 14.06% year-on-year to 3.708 billion yuan.8d ago